Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Overview
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Companies Involved in Therapeutics Development
AveXis Inc
Biogen Inc
Exicure Inc
F. Hoffmann-La Roche Ltd
Ionis Pharmaceuticals Inc
Novartis AG
Sarepta Therapeutics Inc
Shift Pharmaceuticals
Spotlight Innovation Inc
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Drug Profiles
ALB-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Activate SMN2 for Spil Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
braplam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-1V111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SMN for Spil Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SMN1 for Spil Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTP-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONISEC-2.5Rx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LDN-5178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Activate SMN2 for Spil Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
osemnogene abeparvovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMO-25 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Dormant Products
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Discontinued Products
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AveXis Inc, H1 2020
Pipeline by Biogen Inc, H1 2020
Pipeline by Exicure Inc, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by Ionis Pharmaceuticals Inc, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Sarepta Therapeutics Inc, H1 2020
Pipeline by Shift Pharmaceuticals, H1 2020
Pipeline by Spotlight Innovation Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020